Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE SODIUM 20 versus HYPAQUE CYSTO.
HYPAQUE SODIUM 20% vs HYPAQUE-CYSTO
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Intravascular contrast agent for computed tomography (CT) imagingIntravascular contrast agent for angiographyIntravascular contrast agent for urographyIntravascular contrast agent for digital subtraction angiographyOral contrast agent for gastrointestinal studies (off-label)
Intravesical instillation for cystographyRetrograde urethrographyContrast imaging of the lower urinary tract
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Hypaque sodium is not significantly metabolized and is excreted unchanged primarily by glomerular filtration.
Diatrizoate is not metabolized; eliminated unchanged by glomerular filtration.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Minimal, <10%; primarily albumin.
Negligible (approximately 1–5%); does not bind significantly to plasma proteins.
0.2-0.3 L/kg; limited to extracellular fluid.
Approximately 0.2–0.3 L/kg; primarily distributed in extracellular fluid, does not cross intact blood-brain barrier.
Oral: <1% (poor absorption, used for GI opacification); not applicable for IV.
Intravesical/urethral administration: local effect; minimal systemic absorption (<1%).
GFR < 30 mL/min: Avoid use; if necessary, reduce dose by 50% and ensure adequate hydration. GFR 30-60 mL/min: Use with caution, consider lower doses and monitor renal function. GFR > 60 mL/min: No adjustment required.
Contraindicated in patients with anuria or severely impaired renal function (eGFR <30 mL/min/1.73 m²). For eGFR 30-60 mL/min/1.73 m²: use with caution, ensure adequate hydration, and consider lowest necessary dose.
No specific adjustment for mild to moderate impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): Use with caution due to potential for delayed excretion; monitor for adverse effects.
No specific dosage adjustment recommended based on Child-Pugh classification; monitor for signs of hepatotoxicity in severe hepatic impairment.
Intravenous: 1-2 mL/kg (0.2-0.4 g iodine/kg) for excretory urography, not to exceed 30 mL. Intra-arterial: 0.5-1 mL/kg per injection, adjusted based on procedure.
Intravesical: 1-2 mL/kg of 30% solution (maximum 150 mL) for diagnostic imaging; adjust based on bladder capacity.
Start with lower doses (e.g., 50% of adult dose) and titrate upward as needed. Monitor renal function closely due to age-related decline; ensure adequate hydration.
Use lowest effective dose; monitor renal function closely due to age-related decline in GFR; ensure adequate hydration before and after administration.
Not for intrathecal use. Intrathecal administration may cause severe adverse reactions including convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, and death.
Not approved for intrathecal use; severe adverse reactions including seizures, cerebral hemorrhage, and death have occurred following inadvertent intrathecal administration.
["Risk of acute kidney injury, particularly in patients with pre-existing renal impairment, diabetes mellitus, or volume depletion","Anaphylactoid reactions, including anaphylaxis, bronchospasm, and hypotension","Thyroid storm in patients with hyperthyroidism or thyroid nodules","Severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome","Cardiovascular adverse events including arrhythmias and cardiac arrest","Vasovagal reactions","Extravasation leading to tissue injury"]
["Risk of hypersensitivity reactions including anaphylaxis","Renal toxicity in patients with pre-existing renal impairment","Hydration status should be optimized before use","Thyroid toxicity in patients with hyperthyroidism or thyroid nodules"]
["Known hypersensitivity to Hypaque sodium or any of its components","History of anaphylactoid reaction to iodinated contrast media","Intrathecal administration (contraindicated due to risk of neurotoxicity)","Severe renal impairment (e.g., estimated glomerular filtration rate <30 mL/min/1.73 m²)","Concurrent administration of metformin in patients with acute kidney injury or severe renal impairment (risk of lactic acidosis)"]
["Known hypersensitivity to diatrizoate or any component","Thrombophlebitis or active infection in the lower urinary tract","Severe renal impairment (e.g., anuria)"]
Data Pending Review
Data Pending Review
No specific food interactions. Avoid alcohol for 24 hours before procedure to reduce risk of nausea and vomiting. Maintain adequate hydration with clear fluids.
No specific food interactions. Patients should maintain adequate hydration; avoid dehydration prior to imaging procedures.
Hypaque Sodium 20% (diatrizoate sodium) is a radiocontrast agent. It is not known to be teratogenic in humans. However, because it contains iodine, fetal thyroid function may be affected, particularly if exposure occurs during the second or third trimester. The risk of fetal hypothyroidism is theoretical and low with single exposure. Use only if clearly needed.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data; risk cannot be excluded. Avoid first trimester unless essential.
Minimal excretion into breast milk; M/P ratio is not available. The amount ingested by a nursing infant is likely negligible. However, due to potential hypersensitivity or iodine effects, caution is advised. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration, but this may be excessive. Discuss with patient.
Limited data; excreted in breast milk in low quantities. M/P ratio unknown. Use caution; discontinue breastfeeding or drug based on necessity.
No specific dose adjustments are recommended for pregnancy. However, consider the increased plasma volume and renal blood flow in pregnancy; the contrast agent is renally excreted, so clearance may be slightly increased, but no dose change is typically needed. Use the lowest necessary dose.
No dose adjustment required for pregnancy. Physiological changes (increased plasma volume, GFR) may alter drug distribution but no specific dose modification recommended.
Category C
Category C
Administer slowly intravenously to minimize pain and thrombosis risk. Pre-warm to body temperature to reduce viscosity. Ensure adequate hydration before and after use to prevent renal impairment. Have emergency equipment available for anaphylactoid reactions. Use with caution in patients with sickle cell disease due to risk of sickling. Contraindicated in myelography due to neurotoxicity. Check for iodine allergy history.
Hypaque-Cysto (diatrizoate meglumine) is an ionic, high-osmolality contrast agent used for retrograde cystourethrography and voiding cystourethrography. Ensure adequate hydration before and after procedure to reduce risk of contrast-induced nephropathy, though risk is lower with intravesical administration. Monitor for signs of hypersensitivity (urticaria, bronchospasm) particularly in atopic or asthmatic patients. Contraindicated in patients with known iodine allergy or thyrotoxicosis. Use caution in patients with multiple myeloma or diabetes insipidus due to risk of renal impairment.
You may experience a warm sensation or metallic taste during injection.Drink plenty of fluids before and after the procedure to protect your kidneys.Report any symptoms of allergic reaction such as hives, itching, or difficulty breathing immediately.You may have to fast for a few hours before the test depending on the procedure.Inform your doctor if you are pregnant, diabetic, or have kidney problems.You may notice a salty or metallic taste after the injection.
This medication is a contrast dye used during bladder and urinary tract imaging tests.You may experience a warm sensation, metallic taste, or nausea during the procedure; these effects are temporary.Tell your doctor if you have any allergies, especially to iodine or contrast agents, or if you have asthma, thyroid problems, or kidney disease.Drink plenty of fluids before and after the test unless instructed otherwise. Rare but serious allergic reactions can occur; seek immediate medical help if you experience hives, difficulty breathing, or swelling of the face or throat.